12:00 AM
 | 
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Votrient pazopanib: Phase III data

GlaxoSmithKline reported data from the open-label, international Phase III COMPARZ trial in 1,110 patients with locally advanced and/or metastatic RCC who have received no prior systemic therapy showing that once-daily 800 mg Votrient met the primary endpoint of non-inferiority to once-daily 50 mg Sutent sunitinib in median PFS (8.4 vs. 9.5 months). The PFS hazard ratio was 1.047 (95% CI:...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >